TYK2 Inhibitors May Need Little Lab Monitoring in Psoriasis, Lebwohl Says
![<![CDATA[Monitoring and Treatment Selection for Oral TYK2 Inhibitors in Psoriasis]]>](/media/cd/cd8739ab16c5cec7.1280.webp)
Oral TYK2 inhibitors for psoriasis are unlikely to demand meaningful laboratory monitoring, because deucravacitinib's clinical experience has shown no signal across any blood-work parameter. That is the core message from Mark Lebwohl, MD, dermatologist, dean for clinical therapeutics at the Icahn School of Medicine at Mount Sinai, and chairman emeritus of the Mount Sinai dermatology department, in a Dermatology Times Expert Perspectives custom video series.
What will the FDA require?
The agency has not yet defined monitoring requirements for the newer TYK2 agents. Lebwohl expects tuberculosis screening to carry over, since the deucravacitinib package insert already discusses TB screening. The same label references liver and lipid measures, but whether that language repeats in newer labeling remains open.
"We don't know what the FDA will require," Lebwohl said.
He does not anticipate that many of the laboratory tests used with JAK inhibitors will apply to TYK2 inhibitors. He doubts those tests will ever prove useful for this class. Real-world experience with deucravacitinib has been excellent, he said.
"We've not seen an increase in any impact on any of the parameters checked with blood work," Lebwohl said. "So I don't think monitoring will be an important part of this."
For clinicians, that points toward a lighter administrative load than JAK-inhibitor prescribing carries today. Nothing is finalized, though, so watch the labeling when it lands.
How do the orals stack up?
The newer oral TYK2 inhibitors and icotrokinra have all shown superiority to apremilast or deucravacitinib in trials. Deucravacitinib itself already beat apremilast. Lebwohl calls the newer drugs more powerful, and that reshapes his consult room conversation: he now discusses a newer oral or an injectable biologic with patients rather than defaulting to the older oral.
What does this change for treatment selection? Plenty. A patient who wants to avoid injections no longer has to accept a potency compromise, because the newer TYK2 inhibitors appear just as effective as icotrokinra, an IL-23 receptor blocker, according to Lebwohl.
IL-17 or IL-23 blocker?
Both classes look highly effective in this population, Lebwohl said. The decision hinges on speed, arthritis and patient preference.
- Very severe disease: He often reaches for the fastest drugs available, which tend to be IL-17 blockers.
- Psoriatic arthritis: Same lean. "I'll often be inclined to use an IL-17 blocker because they do work fairly well and quickly for psoriatic arthritis," he said.
- Injection-averse patients, or those without arthritis who want a convenient schedule: He often chooses IL-23 blockers, dosed as infrequently as every 2 or 3 months. Those patients also get an oral option on the table — icotrokinra or a TYK2 inhibitor.
That is a practical triage: speed pushes toward IL-17, convenience and needle avoidance push toward IL-23 or an oral.
More choices, fewer treatment failures
The expanding menu is the headline for practice. "Having more choices to treat psoriasis is always better," Lebwohl said. Patients who prefer to avoid injections do not need them. Options exist for those wanting fast results or few doses.
"It is uncommon for me to not be able to successfully treat a psoriasis patient, thanks to all of these options," Lebwohl said.
The forward view hinges on FDA decisions still to come. Once monitoring requirements for the newer TYK2 inhibitors are set — and if they mirror deucravacitinib's benign blood-work record — clinicians can expect an oral psoriasis pathway that combines near-biologic efficacy with minimal laboratory burden.
Source: dermatologytimes.com
Sophie Lindqvist
Show full bio
Market editor covering people, launches and day-to-day practice in Clinical dermatology, inflammatory skin disease and biologics at Derm Field.